The biotech has nominated MB-111, a drug it's developing as a treatment for elevated triglycerides, as its first clinical development candidate.

Researchers at AACR discussed what's next for the drug class, given the disappointing activity of tiragolumab with Tecentriq ...

The nonprofit says its pipeline offers more affordable and accessible therapeutics, including point-of-care CAR-T cell therapy for leukemia and lymphoma.

The company said it took financial hits from the Inflation Reduction Act's Medicare Part D redesign, which included higher ...

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

Biotech firms are engineering smarter, safer gene delivery systems to enhance the safety and efficacy of genetic medicines.

The firm is expecting Phase III readouts this year for its FGFR2b drug bemarituzumab and is advancing a second KRAS inhibitor to the clinic.

The firm enrolled the first patient at Florida's BayCare Morton Plant Hospital, and the study procedure went according to protocol, per an investigator.

The New York-based public benefit corporation is advancing three drug candidates for the extremely rare condition.

The clinical trial will include nearly 150 patients with advanced hepatocellular carcinoma that expresses glypican-3.